Human Nonalcoholic Steatohepatitis on a Chip

May S. Freag,1,2 Bumseok Namgung1,2, Maria E. Reyna Fernandez,1,2 Ermanno Gherardi,3 Shiladitya Sengupta,1,2,4 and Hae Lin Jang1

Nonalcoholic steatohepatitis (NASH), an advanced stage of nonalcoholic fatty liver disease (NAFLD), is a rapidly growing and global health problem compounded by the current absence of specific treatments. A major limiting factor in the development of new NASH therapies is the absence of models that capture the unique cellular structure of the liver microenvironment and recapitulate the complexities of NAFLD progression to NASH. Organ-on-a-chip platforms have emerged as a powerful approach to dynamically model diseases and test drugs. Herein, we describe a NASH-on-a-chip platform. Four main types of human primary liver cells (hepatocytes [HCs], Kupffer cells, liver sinusoidal endothelial cells, and hepatic stellate cells [HSCs]) were cocultured under microfluidic dynamics. Our chip-based model successfully recapitulated a functional liver cellular microenvironment with stable albumin and urea secretion for at least 2 weeks. Exposing liver chips to a lipotoxic environment led to gradual development of NASH phenotypic characteristics, including intracellular lipid accumulation, hepatocellular ballooning, HSC activation, and elevation of inflammatory and profibrotic markers. Further, exposure of the chip to elafibranor, a drug under study for the therapy of NASH, inhibited the development of NASH-specific hallmarks, causing a ~8-fold decrease in intracellular lipids, a 3-fold reduction in number of ballooned HCs, a significant reduction in HSC activation, and a significant decrease in the levels of inflammatory and profibrotic markers compared with controls. Conclusion: We have successfully developed a microfluidic NASH-on-a-chip platform that recapitulates the main NASH histologic endpoints in a single chip and that can emerge as a powerful noninvasive, human-relevant, in vitro platform to study disease pathogenesis and develop novel anti-NASH drugs. (Hepatology Communications 2021;5:217-233).
which can ultimately progress to cirrhosis and liver cancer.\(^{(2)}\) Around 10%-20% of patients with NAFLD develop NASH, characterized by marked fatty change (hepatocyte [HC] ballooning), inflammation, fibrosis, and liver damage\(^{(3)}\) (Fig. 1A). The increased prevalence of NASH is paralleling the dramatic rise in obesity, metabolic syndrome, and sedentary lifestyle because lipid accumulation is the main engine for disease onset and progression resulting in both morphologic and functional disruption of liver tissue.\(^{(4)}\) However, some drugs and chemotherapeutics can also cause NASH through different mechanisms.\(^{(5)}\)

Despite significant progress in understanding its pathophysiology, there is no U.S. Food and Drug Administration-approved therapy for the treatment of NASH.\(^{(6)}\) The financial burden of NAFLD is currently estimated at $100 billion in the United States alone, and the NASH drug market is expected to rise from $1 billion in 2015 to $25 billion by 2025.\(^{(7)}\) While there is an urgent and unmet medical need to develop effective NASH therapies, there are no robust \textit{in vitro} models of the disease currently available. This is a major obstacle for drug discovery, and the need for a human-relevant \textit{in vitro} model of the disease is compelling and would unquestionably open new avenues for drug development.

Rodent models of NASH have been widely used, but significant discrepancies were found between rodent models and human in the transcriptomic profile of the liver tissue, the mechanism of fat accumulation, and degree of liver fibrosis.\(^{(8)}\) On the other hand, two-dimensional (2D) \textit{in vitro} culture models fail to recapitulate the disease as they do not capture the cellular complexity of the liver tissue and the contribution of multiple cell types to disease progression. Initial attempts to address the limitations of 2D cultures have led to the development of 3D models based on immortalized cell lines,\(^{(9)}\) precision-cut liver slices,\(^{(10)}\) or primary human HCs\(^{(11)}\), but these models are limited by viability issues that prevent long-term studies.\(^{(12)}\) More recently, 3D spheroidal cultures of human HCs with hepatic stellate cells (HSCs), endothelial cells, and Kupffer cells (KCs) have been developed and allow long-term studies.\(^{(13)}\) However, the lack of dynamic perfusion is a major drawback of these static culture systems because the activity of HCs under dynamic flow is considerably higher than in static cultures owing to the continuous delivery of oxygen and nutrients and clearance of metabolites and toxic intermediates.\(^{(14)}\)

Organ-on-a-chip platforms have emerged as a powerful approach to dynamically model disease and test drugs. Miniaturized 3D organs have been engineered replicating the key physiological features of specific human microenvironments with precise structural, fluidic, and mechanical control.\(^{(15)}\) Despite the great promise of microfluidic-based 3D organ-on-a-chip models as robust platforms for preclinical studies,\(^{(16)}\) few studies have addressed NASH. For example, exposing HepG2 cells to free
Fatty acid (FFA) overload for 48 hours under microfluidic dynamics led to a significant accumulation of intracellular lipids. However, to the best of our knowledge, there is no dynamic 3D on-chip model integrating the complex cellular interactions between parenchymal (HCs) and nonparenchymal human liver cells (liver sinusoidal endothelial cells [LSECs], KCs, HSCs) to model the development and progression of NASH.

Here, we describe a NASH-on-a-chip in which we coculture the four major types of human primary liver cells (HCs, HSCs, LSECs, and KCs) under microfluidic dynamics, and NASH can be induced by perfusing the disease triggers through an endothelialized inlet microfluidic channel mimicking blood vessels. We demonstrate that our microstructured liver tissue can be maintained under disease-inducing conditions for at least 10 days, simulating the key hallmarks of human NASH, including accumulation of intracellular lipids, hepatocellular ballooning, and production of inflammatory and profibrotic markers. Finally, as a proof of concept, we tested the effectiveness of elafibranor, a potential NASH therapeutic in inhibiting NASH in our liver-on-a-chip model culture.

**Materials and Methods**

**CELL CULTURE**

Four types of primary human hepatic cells (HCs, HSCs, KCs, LSECs) and their corresponding media were purchased from Zen-Bio Inc. Media composition is detailed in the Supporting Information.
FABRICATION OF THE MICROFLUIDIC DEVICE

Triplet microchannel devices, consisting of a middle hydrogel channel surrounded by two side channels, were fabricated with standard photolithography. The fabrication steps of the devices are detailed in the Supporting Information.

CONSTRUCTION OF LIVER-ON-A-CHIP

First, rat tail collagen type I (2 mg/mL; Corning) was prepared according to the manufacturer’s protocol. HSCs (5 x 10^4 cells/mL), KCs (15 x 10^4 cells/mL), and HCs (5 x 10^5 cells/mL) were mixed with the collagen and then injected into the middle channel of the microfluidic chip. The chips were incubated in the incubator (37°C, 5% CO2) for 1 hour until the collagen formed a gel. The chips were then conditioned by a mixture of HC-plating media:H-SC-growth media:KC-plating media at their corresponding cell ratio (10:1:3) through the inlet channel. The chips were then incubated in the incubator for 4 hours. After that, the HC- and KC-plating media were changed to their maintenance media and kept in the incubator for 24 hours. On day 2, LSECs were suspended in LSEC-growth media at a density of 2 x 10^6 cells/mL. Existing media in the chip was removed from the reservoir of the outlet channel, and then 50 µL of LSEC suspension was flowed through the inlet channel. The microfluidic chip was tilted by 90 degrees and kept in the incubator for 1 hour to enable LSECs to adhere to the collagen surface. The microfluidic chip was then incubated once the LSECs were well attached and completely spread onto the collagen surface. Liver steatosis was induced by exposing the liver cells to an overload of long-chain free fatty acids (FFAs) by flowing oleic acid (OA; 0.66 mM) (Sigma) and palmitic acid (PA; 0.33 mM) (Sigma) in the endothelialized channel. We induced NASH by similarly exposing the cells on a chip to OA (0.66 mM), PA (0.33 mM), and lipopolysaccharides (LPS; 10 µg/mL) (Sigma). Here, LPS was added to induce inflammation. To test whether the NASH-on-a-chip platform can be used to detect the efficacy of potential pharmacologic interventions, we exposed the cells to NASH triggers in addition to elafibranor (30 µM) (MedChemExpress LLC). For the preparation of FFAs to apply on a chip, a stock solution of FFAs in dimethyl sulfoxide (DMSO) was diluted in HC-maintenance media enriched with bovine serum albumin (BSA; 1%). In the control group, liver on chips were exposed to HC-maintenance media with the same BSA and DMSO concentration (1% and 0.1%, respectively). All chips were put on the rocker and incubated at 5% CO2 and 37°C. Media of all chips was refreshed every 2 days to maintain constant head pressure during the culture period (14 days). The chips were monitored daily, and any changes in cell morphology were imaged using bright-field microscopy (Nikon Instruments Inc.). Live/dead assay (calcein AM-ethidium homodimer [EthD-1]) (Invitrogen) was performed for assessing cell viability. Additionally, viability of cells in culture was validated using immunolabeling for cleaved-caspase 3. Protocols for biomarker quantification, other experimental procedures, and statistical analysis are detailed in the Supporting Information.

Results

RECAPITULATING LIVER FUNCTION ON A CHIP

We used a triplet microchannel chip to coculture the four types of primary human liver cells under microfluidic dynamics, mimicking the multicellular liver microenvironment (Fig. 1B). First, the three types of human primary liver cells, HCs, HSCs, and KCs, were mixed with collagen type I hydrogel, which resembles the extracellular matrix (ECM) in human liver tissue, and then injected into the middle channel of the chip to create a 3D coculture. The LSEC monolayer was subsequently established on the lateral surface of the
collagen hydrogel, mimicking the perforated endothelial lining in an in vivo liver sinusoid (Fig. 1C). The four types of liver cells could communicate with each other by direct cell to cell contact and factors secreted in the milieu. In our study, the HCs and nonparenchymal cells, including HSCs, LSECs and KCs, were cocultured at a ratio of 10:1:20:3 where the ratio between HCs, HSCs, and KCs (10:1:3) was similar to the cellular composition of in vivo liver. LSECs were cultured in our system at a relatively higher ratio to ensure formation of a continuous monolayer on the whole lateral surface of the ECM.

The key features of the four hepatic cells in the 3D liver chip were characterized by immunofluorescence staining. After 1 day, LSECs formed a monolayer expressing their characteristic platelet endothelial cell adhesion molecule/cluster of differentiation (CD)31 (Fig. 2Ai, red). In the collagen matrix, the KCs attained a rounded structure expressing their characteristic CD68 protein (blue; insert in Fig. 2Aii),

![Image](https://example.com/image.png)

**FIG. 2.** Construction of liver-on-a-chip. (A) Recapitulation of the liver cellular microenvironment on a chip. (Ai) LSECs forming a continuous monolayer in the lateral channel. (Aii) Collagen compartment containing KCs (blue), HSCs (green), and HCs (red); scale bars are 25 µm. (Aiii) Merged image showing both endothelialized channel and collagen compartments. (B) Representative brightfield microscope image showing the orientation of HCs (red), HSCs (green), and KCs (blue) in the collagen matrix (gray). (C) Representative confocal microscope image of the 3D arrangement of HCs (red), HSCs (green), and KCs (blue) in a collagen matrix. (D) Live/dead assay of liver cells after 14 days of initial culture. (E) Functional activity of liver-on-chips, including albumin, urea, and lactate production. Data are presented as mean ± SEM; n = 3. Significance was calculated using ANOVA followed by the Kruskal-Wallis test, *P < 0.05 and **P < 0.01. Trapezoids with dashed lines indicate the posts in the device for the collagen boundary; thus, cells are not present over the posts. Abbreviation: conc., concentration.
while HSCs showed their characteristic stellate-like shape with branched structures like astrocytes (insert in Fig. 2Aii; the green color corresponded to the vimentin staining). HCs showed their distinct polygonal shape with red-stained cytokeratin (insert in Fig. 2Aii). A brightfield microscope image of the orientation of HCs (red), HSCs (green), and KCs (blue) in the collagen matrix (gray) is shown in Fig. 2B, while a representative confocal microscope image of the 3D arrangement of HCs (red), HSCs (green), and KCs (blue) in a collagen matrix is shown in Fig. 2C. These cells in the collagen matrix showed high viability (>85%) even after 14 days of initial culture (Fig. 2D), indicating that our chip-based liver tissue modeling system enabled adequate exchange of nutrients and gases to the cells for the long-term culture.

To further assess the synthetic, metabolic, and detoxification function of cells in our liver-on-a-chip, we perfused the liver cells with a high concentration of FFAs with and without LPS through the LSEC-monolayered microfluidic channel for 10 days. We then analyzed the progression of NASH hallmarks, including intracellular lipid accumulation, hepatocellular ballooning, inflammation, and fibrosis, qualitatively and quantitatively (Fig. 3A). The exposure of liver cells to a high concentration of FFAs for 10 days led to a significant accumulation of neutral lipids inside the HCs that manifested as a ~3-fold increase in red fluorescence intensity (HCS lipidTOX RED staining) compared to cells cultured under healthy conditions (Fig. 3B), indicating steatosis development. Similarly, we could visualize significant changes in the morphologies of HCs due to lipotoxic lethal and sublethal injury and apoptosis at different time points on a chip (Fig. 4A). Liver cell apoptosis and cytotoxicity were further examined biochemically by cleaved caspase-3 staining and lactate dehydrogenase (LDH) activity assessment, respectively.

Liver cells cultured under NASH triggers (FFAs + LPS) showed a significantly higher number of cleaved caspase-3-positive cells (~3-fold) and significantly elevated levels of LDH activity compared with controls as early as day 4 when the chip was challenged with lipotoxic stress (Fig. 4); this indicated the onset of liver injury associated with NASH development on our chip model. Indeed, LDH levels are classically considered a biomarker for the viability of cells. We observed a significant increase in the levels of LDH activity in the control arm on day 10 (but not at other time points) compared with the day 2 control arm (analysis of variance [ANOVA] followed by the Kruskal-Wallis test; adjusted $P = 0.01$). This increase in LDH levels is consistent with that normally associated with primary cell–based long-term cultures; interestingly, the total LDH release was maintained at minimal values (below 2 U/L) compared to the levels seen in these previous studies. However, we validated the viability of our system using two additional approaches (cleaved-caspase expression analysis and calcein AM/EthD-1 labeling, which is a live/dead assay). A minimal cleaved caspase 3 signal was evident in the control arm on day 10 (Fig. 4B). Live cells enzymatically convert nonfluorescent cell-permeant calcein AM to the intensely fluorescent calcein. EthD-1 enters cells with damaged membranes (but is excluded by intact plasma membrane of live cells) and undergoes a 40-fold enhancement of fluorescence in the presence of damaged membranes. We observed a minimal cleaved caspase 3 signal and live cells on day 10 (Fig. 4B).

**INDUCTION AND MORPHOLOGICAL CHARACTERIZATION OF NASH-ON-A-CHIP**

After establishing the viability and metabolic functionality of the cells in the dynamic 3D chip, we next exposed the liver cells to a lipotoxic stimuli to induce NASH-on-a-chip (Fig. 1C). As described earlier, we
Fig. 3. Histologic hallmarks of NASH. (A) Schematic representation of histologic hallmarks of NASH, including inflammation, HSC activation, and lethal and sublethal injury in HCs cultured under lipotoxic stress. (B) Steatosis on-a-chip. Representative images of HCs cultured under (Bi) healthy or (Bii) lipotoxic conditions for 10 days. (Biii) Mean fluorescence intensity of neutral lipid staining of HCs was quantified and plotted against healthy controls after 10 days of disease induction. (Biv) Magnified image of HCs cultured under lipotoxic stress. Data are presented as mean ± SEM; n ≥ 20. Significance was calculated by the nonparametric Mann-Whitney test, ****P < 0.0001. Abbreviation: a.u., arbitrary unit.
of fluorescence following binding to nucleic acids, thereby producing a bright red fluorescence in dead cells. The ratio of live to dead cells in the control arm was found to be 90.4% (viable) to 9.6% (dead) on day 5, and ~85% cell viability was observed after 10 days of initial culture (Fig. 2D; Supporting Fig. S1A).
Together, with good functionality evidenced by stable urea and albumin secretions at late time points (Fig. 2E), this supports that the chip was functionally viable during the study period. However, this baseline increase in LDH over time means the models still need to evolve to truly mimic the human liver.

Hepatocellular ballooning is a hallmark of NASH, and ballooned HCs are greatly involved in the disease pathogenesis by releasing profibrogenic factors, such as hedgehog (Hh) ligands, that induce hepatic fibrogenesis by paracrine signaling. A representative image of immunostained ballooned HCs with its characteristic features is shown in Fig. 4Di. The ballooned cells showed their distinct swollen and rounded morphology, displaced nucleus (blue), and accumulation of ubiquitinated proteins (green). Based on these unique features of ballooned HCs, emergence and the incidence rate of hepatocellular ballooning can be used for measuring the disease progression stage of NASH. Chips that were cultured under the NASH triggers for 10 days showed a significantly higher number of ballooned HCs (~14.5-fold) compared to the control group (Fig. 4Dii), which further confirmed disease induction and progression in our NASH-on-a-chip platform.

HSCs are the main contributors to liver fibrosis. During NASH progression, quiescent HSCs undergo rapid activation and transdifferentiation into myofibroblast-like cells with fibrogenic, proliferative, and contractile characteristics. Myofibroblasts exhibit a characteristic morphology of large bundles of microfilaments extending along the cell axis. Increased expression of α-smooth muscle actin (α-SMA) is one of the indicative markers of HSC activation and the transdifferentiated phenotype. In this respect, we observed the morphology of the HSCs (Fig. 5Ai-iv) and quantified the expression level of α-SMA after immunofluorescence staining after 10 days of disease induction. Under NASH conditions, HSCs exhibited a significantly higher level (~7.7-fold; Fig. 5Av) compared to the control group (Fig. 5Avi), which further confirmed disease induction and progression in our NASH-on-a-chip platform.

INFLAMMATORY AND PROFIBROTIC BIOMARKERS IN NASH-ON-A-CHIP

To assess NASH-associated inflammation in our microfluidic chip, media effluents from liver tissue cultured on chips were collected at day 5 and day 10 after exposure to lipotoxic conditions to analyze inflammatory markers that are reported to be elevated during NASH development, including monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory protein 1α (MIP1α), and tumor necrosis factor α (TNF-α) (Fig. 7). Mean ± SEM MCP1 concentrations in media from FFA-treated (nonalcoholic fatty liver [NAFL]) and FFA + LPS-treated (NASH) groups were 3.23 ± 0.69 ng/mL and 3.22 ± 0.35 ng/mL, respectively, which were significantly higher than the MCP1 concentration (mean ± SEM, 1.25 ± 0.22 ng/mL) detected in media from controls (Fig. 7A). MIP1α concentration in the NASH group (mean ± SEM, 282.21 ± 26.45 pg/mL) was significantly higher compared with both the NAFL group (mean ± SEM, 174.52 ± 65.83 pg/mL) and
Fig. 5. Fibrosis on-a-chip. (A) Representative fluorescence images of HSCs after α-SMA staining under (Ai) healthy, (Aii) NAFL, and (Aiii) NASH conditions. (Av) Magnified image of activated HSCs under the NASH condition. (Avi) Mean fluorescence intensity of α-SMA-stained HSCs and (Avi) average number of activated HSCs under healthy, NAFL, and NASH conditions after 10 days of disease induction. (B) Representative fluorescence images of COL1A1 staining under (Bi) healthy, (Bii) NAFL, and (Biii) NASH conditions. (Biv) Magnified image showing COL1A1 expression in HSCs under the NASH condition. (Bv) Mean fluorescence intensity of COL1A1 under healthy, NAFL, and NASH conditions after 10 days of disease induction. (Bvi) Representative fluorescence image showing COL1A1 and α-SMA expression in activated HSCs. (C) Representative fluorescence images of TIMP-1 staining under (Ci) healthy, (Cii) NAFL, and (Ciii) NASH conditions. (Civ) Magnified image showing TIMP-1 expression in HSCs under the NASH condition. (Cv) Mean fluorescence intensity of TIMP-1 under healthy, NAFL, and NASH conditions after 10 days of disease induction. (Cvi) Representative fluorescence image showing TIMP-1 and α-SMA expression in activated HSCs. Data are presented as mean ± SEM; n ≥ 10. Significance was calculated using ANOVA followed by the Kruskal-Wallis test; *P < 0.05, **P < 0.01, ***P < 0.005, and ****P < 0.0001. Abbreviations: a.u., arbitrary units; CK-Pan, pan-cytokeratin; DAPI, 4′,6-diamidino-2-phenylindole.
control groups (mean ± SEM, 153.85 ± 14.55 pg/mL) (P < 0.05). A similar trend was also observed for TNF-α, where the NASH group showed the highest concentration of TNF-α (mean ± SEM, 1.69 ± 0.50 ng/mL) while the NAFL and control groups were 0.95 ± 0.22 ng/mL and 0.67 ± 0.06 ng/mL, respectively (Fig. 7C). Such a significant difference among groups was not observed at day 5, which again confirmed the gradual NASH progression in our chip in a physiologically relevant manner.

Furthermore, we measured the expression levels of transforming growth factor β (TGF-β) and osteopontin (OPN) (Fig. 7D,E). TGF-β is a well-known regulator of fibrosis as it promotes excessive secretion of ECM proteins by HSCs, especially collagens, and inhibits the production of matrix-degrading...
proteases, thus preventing ECM degradation. OPN is another important biomarker that has been proven to have a positive correlation with liver fibrosis because it interacts with HSC surface integrins (αvβ3) resulting in activation of the phosphoinositide 3-kinase (PI3K)/phosphorylated AKT serine/threonine kinase 1 (pAkt)/nuclear factor kappa B (NF-κB) signaling pathway and subsequent up-regulation of collagen type I and modulation of the HSC profibrogenic phenotype. It was found that concentration levels of both TGF-β and OPN detected in the media collected from chips cultured under lipotoxic conditions were significantly higher than those cultured under healthy conditions. The mean ± SEM TGF-β concentration in media effluent collected from NAFL and NASH groups

FIG. 7. Assessment of inflammatory and profibrotic makers of liver cells cultured under healthy and lipotoxic conditions. Concentration levels of inflammatory markers (A) MCP1, (B) MIP1α, and (C) TNF-α and profibrotic markers (D) TGF-β and (E) OPN in the effluent media of control, NAFL, and NASH groups after 5 and 10 days. Data are presented as mean ± SEM; n = 3. Significance was calculated using two-way ANOVA followed by the Bonferroni test, *P < 0.05, **P < 0.01, ***P < 0.005, and ****P < 0.0001. Abbreviation: conc., concentration.
was 35.33 ± 3.92 µg/mL and 37.83 ± 1.55 µg/mL, respectively, while significantly lower TGF-β concentration (mean ± SEM, 23.17 ± 0.80 µg/mL) was detected in the media of the control group. The concentration of OPN in chips that were exposed to NASH triggers showed the highest concentration (mean ± SEM, 2.66 ± 0.47 ng/mL) compared with the control group (mean ± SEM, 0.41 ± 0.02 ng/mL) or NAFL group (mean ± SEM, 0.41 ± 0.03 ng/mL).

TESTING DRUG EFFICACY USING THE NASH-ON-A-CHIP PLATFORM

We next tested the feasibility of our NASH-on-a-chip as a drug-testing platform. Elafibranor is a dual agonist for peroxisome proliferator-activated receptors (PPAR-α/δ), which are highly involved in regulation of fatty acid metabolism in HCs. It attenuates the inflammation and fibrosis mediated by NF-κB and activator protein 1 signaling pathways (Fig. 8A).(30) We applied the drug through the endothelialized microfluidic inlet channel to mimic drug circulation in blood vessels in vivo. Treatment was started simultaneously with lipotoxic stress (NASH group), as described earlier. We then compared the expression level of NASH hallmarks, including lipid accumulation, hepatocellular ballooning, inflammation, and fibrosis, with and without application of drugs. Exposure of FFA + LPS-treated liver cells to elafibranor significantly prevented fat accumulation within the HCs, which was manifested as a ~7.7-fold decrease in the fluorescence intensity of stained neutral lipids compared to the control NASH group (LPS + FFA only, no elafibranor) (Fig. 8B). Our results are consistent with the effect of elafibranor on reducing lipid accumulation, as reported by Boeckmans et al.\(^{[32]}\) in hepatic cells differentiated from human skin-derived precursors and match the antisteatotic effects of elafibranor that have been reported in clinical trials.\(^ {30}\)

In addition, the expression of elafibranor protected liver cells against injury associated with NASH development, evidenced by the significantly lower number of ballooned (~3-fold; Fig. 8D) and apoptotic and dead HCs (2.7-fold) as well as reduced levels of LDH activity (Supporting Fig. S1). Furthermore, we observed that elafibranor significantly prevented the transdifferentiation of HSCs to myofibroblasts, evidenced by a ~13-fold lower expression of α-SMA and a ~6-fold lower number of activated HSCs in the elafibranor group compared with the NASH group (Fig. 8C). The expression of fibrosis-related proteins (TIMP-1, COL1A1) and the number of TIMP-1⁺ and COL1A1⁺ HSC cells were significantly decreased when elafibranor was added to the NASH chips (Supporting Fig. S2), consistent with the antifibrotic action of elafibranor observed in clinics.\(^ {31}\)

The effect of elafibranor on NASH-associated inflammation was assessed by quantification of representative inflammatory chemokines in the media collected from NASH-on-chips. The application of elafibranor reduced the NASH-associated increased expression of inflammatory chemokines, like MCP1 (Fig. 8Ei), MIP1α (Fig. 8Eii), and TNF-α (Fig. 8Eiii). For example, the concentration of MCP1 in the elafibranor group (mean ± SEM, 1.11 ± 0.19 ng/mL) was significantly lower than the concentration detected in the NASH group (mean ± SEM, 3.22 ± 0.35 ng/mL). Additionally, the expression of other fibrosis mediators, including TGF-β (Fig. 8Eiv) and OPN (Fig. 8Ev), in the NASH groups was also attenuated when elafibranor was added. For example, the mean ± SEM expression level of OPN was dramatically decreased in the elafibranor group to 0.65 ± 0.03 ng/mL, with no significant difference to the baseline controls (mean ± SEM, 0.41 ± 0.02 ng/mL).

Discussion

Modeling complex diseases using organ-on-a-chip platforms is an emerging and general paradigm.\(^{[32]}\) By leveraging human primary cells, ECM, and microfluidics, we have successfully extended this approach to NASH and developed a “NASH-on-a-chip” culture system capable of (i) maintaining primary human liver cells viable and functional over a period of at least 2 weeks (Fig. 2); (ii) recapitulating the morphologic and biochemical hallmarks of the human disease (Figs. 3-7); and (iii) validating the activity of elafibranor, a lead therapeutic in advanced stages of development for NASH therapy (Fig. 8). The NASH-on-a-chip described here is a clear advance over previous static, 3D, spheroidal cultures and may yield new insights on disease mechanisms and progression and support new programs of drug discovery.\(^ {33}\)

HCs account for ~78% of liver volume\(^ {34}\) and are responsible for most of the vital liver functions, such as protein synthesis, metabolic regulation, and
detoxification.\(^{35}\) We used collagen type I, the major matrix component of liver tissue,\(^{21,36}\) to enhance the growth and preserve the differentiated state of HCs.\(^{14}\) More importantly, culturing the HCs in a 3D collagen matrix allows closer simulation to the spatial distribution of cells in vivo because it facilitates...
cell-to-cell and cell-to-matrix interactions in all directions. For example, HCs cultured in a 3D collagen gel showed superior activity compared to HCs cultured as a monolayer on a collagen gel-coated 2D surface. In addition, we used dynamic flow conditions to control the supply of oxygen, nutrients, and other soluble factors to the culture, thus enhancing cell survival and activity, as measured by albumin and urea secretion over 14 days (Fig. 2). Interestingly, lactate production tendency in our liver chips matched well the reported extraordinary capacity of HCs to tolerate hypoxia and satisfy energy requirements by anaerobic glycolysis (Fig. 2E). We observed a reduction in lactate secretion over 14 days (Fig. 2). Interestingly, lactate production tendency in our liver chips matched well with the reported extraordinary capacity of HCs to tolerate hypoxia and satisfy energy requirements by anaerobic glycolysis (Fig. 2E). We observed a reduction in lactate secretion over 14 days (Fig. 2).

We selected PA and OA, the most common long-chain FFAs that accumulate in the liver of patients with NASH, as lipotoxic stressors in the culture system and used them at concentrations typically present in the plasma of patients with NASH. Further, we used LPS to trigger disease progression because recent clinical data indicate that patients with NAFLD and NASH have high serum TIMP-1 expression. It is widely known that TIMP-1 is up-regulated in liver tissue during hepatic fibrogenesis and that it promotes fibrosis by subsequent accumulation of ECM proteins in the injured liver. Although TIMP-1 is mainly secreted by HSCs and KCs in the liver, it is also reported to be expressed by HCs under diseased conditions, such as CCl4-induced liver fibrosis. This is in agreement with our findings as we observed elevated TIMP-1 expression in HSCs, KCs, and HCs under a NASH condition. Increased expression of TIMP-1 and COL1A1 and the increased number of α-SMA-positive HSCs in the FFA + LPS-treated chips versus the FFA-treated chips (Fig. 5) suggest that LPS can potentially drive the phenotype toward NASH even though clinically the levels of LPS are similar in NAFL and NASH.

It has been reported that the Hh signaling pathway is widely involved in the development of fibrosis in patients with NASH, where both ballooned and apoptotic HCs produce and release SHh ligands. Binding of SHh ligands to the SHh receptor on the surface of HSCs leads to activation of smoothened (Smo) nuclear accumulation of GLI2 and subsequent transcription of GLI1 and its target genes leading to activation and differentiation of HSCs. Interestingly, this finding is mirrored in our NASH model (Fig. 6), highlighting another advantage of our NASH model that allows crosstalk between different types of liver cells by either direct cell to cell contact and/or factors released in the matrix.

While treatment with FFA alone resulted in up-regulation of MCP1 and TGF-β, the addition of LPS resulted in activation of MCP1, MIP1α, TNF-α, and OPN in a time-dependent manner, confirming that distinct pathways are involved in and can discriminate different stages of the disease leading to HSC activation and proliferation. Hepatocellular lipotoxic stress and apoptotic cell death further act as the main triggers for stimulation of innate immune cells to elicit inflammatory response, which in turn leads to further hepatocellular damage and death. KCs contribute to tissue inflammation through secretion of ligand pathways and consistent with this mechanism of paracrine signaling. To the best of our knowledge, this is the first in vitro model platform that has shown systematic morphologic changes of HCs due to lethal and sublethal injury during NASH progression, indicating that our NASH-on-a-chip system can be useful to study NASH pathogenesis.
MCP1 and TNF-\(\alpha\),\(^{(27)}\) and the results of our culture system (Figs. 7 and 8) indicate that the engineered NASH-on-chips platform captures the key proinflammatory and profibrotic features of the progression from NAFL to NASH.

A major advantage of using a human disease-on-a-chip model is that it can be used to study new chemical entities in a preclinical setting.\(^{(45)}\) We observed that elafibranor could inhibit disease progression and fibrosis, as observed in clinical trials.\(^{(46)}\) Interestingly, elafibranor failed to inhibit the late induction of TGF-\(\beta\) but inhibited the induction of other molecular markers, including the early increase in OPN induced by the combination of FFA + LPS. This is consistent with previous reports where PPAR has been implicated in signaling pathways downstream of TGF-\(\beta\).\(^{(47)}\) These results indicate that monotherapies, such as elafibranor, may impact certain steps of NASH progression, but the complexity of NASH suggests that combined therapies may ultimately be more successful in disease control. The NASH-on-a-chip culture system appears ideal for studying the prospective synergy of drugs that target distinct pathogenetic components of the disease, such as HC death, inflammation, and fibrosis, leading to the development of novel combination therapies.

In conclusion, we have developed a 3D microfluidic culture system that captures the essential morphologic features of NAFL and NASH and the progression from NAFL to NASH. Of further note is the endothelialized inlet microfluidic channel and outlet microfluidic channel in our chip-based device that mimic a blood vessel for drug diffusion and allow easy collection of culture medium for protein analysis for NASH molecular markers. We also envisage further and major developments of the culture system, namely, (1) the design of the 3D architecture of liver tissue by integrating 3D printing, (2) the use of more complex ECM instead of the collagen type I used in the current study, and (3) the integration of immune cells beyond the tissue-resident KCs included in the present design.\(^{(48)}\) Overall, we believe that the platform described can have a potential contribution in the medical field by providing a noninvasive, human cell-based, \textit{in vitro} model of NASH that can make significant contributions to the understanding of NASH pathogenesis and development of novel NASH therapies.
21) Chung SI, Moon H, Ju H-L, Cho KJ, Kim DY, Han K-H, et al. Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist’s perspective. Expert Rev Gastroenterol Hepatol 2011;5:223-231.
22) Caldwell S, Ikura Y, Dias D, Isomoto K, Yabu A, Moskaluk C, et al. Hepatocellular ballooning in NASH. J Hepatol 2010;53:719-723.
23) Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321.
24) Friedman SL. Non-alcoholic steatohepatitis: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008;88:125-172.
25) Lackner C. Hepatocellular ballooning in nonalcoholic steatohepatitis. J Cell Biol 1977;72:441-455.
26) Wang YJ, Liu HL, Guo HT, Wen HW, Liu J. Primary hepatocyte culture in collagen gel mixture and collagen sandwich. World J Gastroenterol 2004;10:699-702.

Supporting Information

Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep4.1647/supinfo.